This article was written by Dr Anna D. Baker, Executive Committee Chair, GBM AGILE Trial, and was first published in the 2016/17 edition of Brain Tumour, the IBTA's annual magazine that is distributed globally and free of charge in 113 countries and at international neuro-oncology and cancer conferences around the world. Read the full issue online and find out more here.
Glioblastoma is Unacceptable
Tens of thousands of people are diagnosed with glioblastoma multiforme (GBM) on a global basis each year. With a median survival of 14 months and only 5% of patients living five years or longer, GBM is a grim diagnosis. Despite hundreds of GBM clinical trials, testing hundreds of agents, there have only been four approved GBM treatments, and the dismal prognosis for GBM patients has not changed in decades. Read More